(8–10) Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are both B-cell maturation antigen (BCMA)-targeted CAR T cell therapies approved for the treatment of relapsed/refractory multiple myeloma after four or more prior lines of therapy (11, 12). Here, TNFRSF17 is linked to AL amyloidosis.